Revolution Medicines (RVMD) Operating Income (2019 - 2026)

Revolution Medicines' Operating Income history runs 8 years deep, the most recent figure standing at -$445.2 million for Q1 2026.

• On a quarterly basis, Operating Income fell 84.92% year-over-year to -$445.2 million in Q1 2026; TTM through Mar 2026 was -$1.4 billion, a 75.68% decrease from a year earlier, with the FY2025 full-year figure at -$1.2 billion, down 71.48% from the prior year.
• Operating Income slipped to -$445.2 million in Q1 2026 per RVMD's latest filing, from -$361.6 million in the prior quarter.
• Across five years, Operating Income topped out at -$57.9 million in Q1 2022 and bottomed at -$445.2 million in Q1 2026.
• The 5-year median for Operating Income is -$156.6 million (2024), against an average of -$180.2 million.
• Across the five-year window, Operating Income decreased 16.62% in 2022 and plunged 191.67% in 2023, its largest moves.
• Year by year, Operating Income stood at -$61.7 million in 2022, then plunged by 191.67% to -$180.0 million in 2023, then dropped by 20.18% to -$216.3 million in 2024, then slumped by 67.18% to -$361.6 million in 2025, then retreated by 23.12% to -$445.2 million in 2026.
• Per Business Quant, the three latest RVMD Operating Income figures stand at -$445.2 million (Q1 2026), -$361.6 million (Q4 2025), and -$315.3 million (Q3 2025).